Association between bisphosphonate therapy and outcomes from rehabilitation in older people

被引:5
作者
Goodbrand, James A. [1 ]
Hughes, Lloyd D. [1 ]
Cochrane, Lynda [2 ]
Donnan, Peter T. [2 ]
McGilchrist, Mark [3 ]
Frost, Helen [4 ]
McMurdo, Marion E. T. [1 ]
Witham, Miles D. [1 ]
机构
[1] Univ Dundee, Ageing & Hlth, Dundee, Scotland
[2] Univ Dundee, Epidemiol & Biostat Unit, Dundee, Scotland
[3] Univ Dundee, Hlth Informat Ctr, Dundee, Scotland
[4] Univ Stirling, Nursing Midwifery & Allied Hlth Profess Res Unit, Stirling, Scotland
关键词
Older; Bisphosphonate; Rehabilitation; Resilience; POSTMENOPAUSAL OSTEOPOROSIS; INPATIENT REHABILITATION; CARDIOVASCULAR-DISEASE; HIP FRACTURE; IN-VIVO; MORTALITY; CONNEXIN-43;
D O I
10.1016/j.archger.2017.01.017
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
030301 [社会学]; 100201 [内科学];
摘要
Background: Bisphosphonate therapy may have actions beyond bone, including effects on cardiovascular, immune and muscle function. We tested whether bisphosphonate treatment is associated with improved outcomes in older people undergoing inpatient rehabilitation. Methods: Analysis of prospectively collected, linked routine clinical datasets. Participants were divided into never users of bisphosphonates, use prior to rehabilitation only, use after rehabilitation only, and current users (use before and after rehabilitation). We calculated change in 20-point Barthel scores during rehabilitation, adjusting for comorbid disease and laboratory data using multivariable regression analysis. Cox regression analyses were performed to analyse the association between bisphosphonate use and time to death or hospitalisation. Results: 2797 patients were included in the analysis. Current bisphosphonate users showed greater improvement in Barthel score during rehabilitation than non-users (5.0 points [95% CI 4.3-5.7] vs 3.8 [95% CI 3.6-3.9]), but no difference compared to those receiving bisphosphonates only after discharge (5.1 [95% CI 4.6-5.5]). Previous bisphosphonate use was significantly associated with time to death (adjusted hazard ratio 1.41 [95% CI 1.15-1.73]) but less strongly with time to combined endpoint of hospitalisation or death (adjusted hazard ratio 1.18 [95% CI 0.98-1.48]). Use after discharge from rehabilitation was associated with reduced risk of death (adjusted hazard ratio 0.64 [95% CI 0.55-0.73]; hazard ratio per year of bisphosphonate prescription 0.98 [95% CI 0.97-0.99]). Conclusion: Bisphosphonate use is unlikely to be causally associated with improved physical function in older people, but continuing use may be associated with lower risk of death. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:195 / 200
页数:6
相关论文
共 33 条
[1]
Vitamin D status and response to treatment in post-menopausal osteoporosis [J].
Adami, S. ;
Giannini, S. ;
Bianchi, G. ;
Sinigaglia, L. ;
Di Munno, O. ;
Fiore, C. E. ;
Minisola, S. ;
Rossini, M. .
OSTEOPOROSIS INTERNATIONAL, 2009, 20 (02) :239-244
[2]
Molecular mechanisms of liver preconditioning [J].
Alchera, Elisa ;
Dal Ponte, Caterina ;
Imarisio, Chiara ;
Albano, Emanuele ;
Carini, Rita .
WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (48) :6058-6067
[3]
Oral bisphosphonates are associated with reduced mortality after hip fracture [J].
Beaupre, L. A. ;
Morrish, D. W. ;
Hanley, D. A. ;
Maksymowych, W. P. ;
Bell, N. R. ;
Juby, A. G. ;
Majumdar, S. R. .
OSTEOPOROSIS INTERNATIONAL, 2011, 22 (03) :983-991
[4]
Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis [J].
Bolland, Mark J. ;
Grey, Andrew B. ;
Gamble, Greg D. ;
Reid, Ian R. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (03) :1174-1181
[5]
Cardiovascular disease and osteoporosis: is there a link between lipids and bone? [J].
Burnett, JR ;
Vasikaran, SD .
ANNALS OF CLINICAL BIOCHEMISTRY, 2002, 39 :203-210
[6]
Burton LA, 2010, CLIN INTERV AGING, V5, P217
[7]
Osteoporosis Medication and Reduced Mortality Risk in Elderly Women and Men [J].
Center, Jacqueline R. ;
Bliuc, Dana ;
Nguyen, Nguyen D. ;
Nguyen, Tuan V. ;
Eisman, John A. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (04) :1006-1014
[8]
Extra-skeletal effects of bisphosphonates [J].
Corrado, Addolorata ;
Santoro, Nella ;
Cantatore, Francesco Paolo .
JOINT BONE SPINE, 2007, 74 (01) :32-38
[9]
Pharmacology of bisphosphonates [J].
Cremers, Serge ;
Papapoulos, Socrates .
BONE, 2011, 49 (01) :42-49
[10]
Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress [J].
George, Jacob ;
Struthers, Allan D. .
VASCULAR HEALTH AND RISK MANAGEMENT, 2009, 5 :265-272